Issued on behalf of GoldHaven Resources Corp.
VANCOUVER, British Columbia, Jan. 07, 2026 (GLOBE NEWSWIRE) — Equity Insider Market Intelligence Brief – The era of abundance is over.
The digital economy scales infinitely. The physical economy has hit a wall.
We are running out of the inputs that make civilization function. Cheap uranium to power the grid. Strategic metals to build the defense stack. Clinical data to stop the cancer. Sovereign technology to secure the nation.
The companies below don’t sell growth. They own the bottleneck.
If you cannot source the tungsten, you cannot build the missile. If you cannot extract the uranium, you cannot run the data center. If you cannot generate the survival data, you cannot approve the drug.
This is not a market rotation. This is a scramble for inventory.
Investors are buying these assets because they are the choke point. The system cannot function without them.
THE STRATEGIC DISCOVERY
GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) just delivered preliminary assay results from its Magno Project that redefine the asset class. This is not incremental exploration data. This is “Bonanza” grade confirmation.
On January 6, the company reported silver values as high as 2,370 g/t, alongside tungsten at 6,550 ppm and indium at 334 ppm. The market is treating this as a precious metals story. The data reveals a strategic materials inventory.
Tungsten is a defense-critical metal. It anchors armor-piercing munitions and high-temperature aerospace components. Indium is essential to touchscreen manufacturing and solar panel production. Silver remains irreplaceable in electronics and photovoltaics.
This is a “Commodity Super-Cycle” asset in a jurisdiction that just removed the bottleneck.
In December, BC Premier David Eby announced accelerated permitting reforms, committing to a “one project, one review” system. The province is explicitly targeting critical minerals development as an economic priority. GoldHaven is advancing a district-scale discovery just as the regulatory framework shifts to enable it.
The geologic context matters. The Magno Property sits in the Cassiar District, a historically productive mineral belt with existing infrastructure. This is not grassroots speculation. It is confirmation drilling on a known system that is delivering grades above economic thresholds.
The valuation disconnect is stark. With gold approaching all-time highs and strategic metals facing structural deficits, GoldHaven is trading as a junior explorer. The assay data positions it as a near-term production candidate in a Tier-1 jurisdiction with newly streamlined permitting.
The inflection is measured in quarters, not years.
Read this and more news for GoldHaven Resources at: https://equity-insider.com/2025/10/02/the-goldhaven-story-two-continents-one-strategy-systematic-historic-gold-district-exploration-2/
THE CLINICAL VALIDATION
Oncolytics Biotech Inc. (NASDAQ: ONCY) solidified its registration path today with the expansion of its Scientific Advisory Board, adding globally recognized experts from Memorial Sloan Kettering and MD Anderson.
This is the institutional seal of approval the market has been waiting for.
On January 7, the company announced the addition of Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris to its GI Tumor Scientific Advisory Board. These are not academic advisors collecting fees. They are the oncologists who design the pivotal trials that lead to FDA approvals.
The timing is critical. This follows the December 16 data release showing a 33% objective response rate in KRAS-mutant colorectal cancer patients treated with pelareorep plus checkpoint inhibitors. That response rate is the difference between “interesting biology” and “registration-track asset.”
Key opinion leaders do not attach their names to failing programs. They join assets with approvable data and commercial trajectories. The presence of MSK and MD Anderson leadership signals that Oncolytics has transitioned from science project to registration candidate.
The market is underpricing the de-risking event. Colorectal cancer is a $15 billion global market. KRAS mutations account for 40% of cases and have historically been immune to checkpoint therapy. Pelareorep is unlocking that resistance.
With hard survival data in hand and the scientific elite now steering pivotal trial design, Oncolytics has crossed the credibility threshold. The bottleneck in oncology is not capital. It is clinical proof validated by the institutions that matter.
Read this and more news for Oncolytics Biotech at:
https://equity-insider.com/2025/03/18/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/
THE AUTONOMY ENGINE
VisionWave Holdings Inc. (NASDAQ: VWAV) recently fundamentally altered its valuation profile with the acquisition of QuantumSpeed, a computational acceleration engine designed to solve the most critical constraint in AI and defense infrastructure: decision latency.
The world has enough sensors. The problem is processing the signal before the threat executes. In hypersonic warfare and autonomous systems, milliseconds determine survival. If it takes minutes to analyze the data, the target is already gone.
Recently, VisionWave secured the solution.
QuantumSpeed is not incremental software. It is a pre-commercial acceleration architecture independently valued at $99.6 million by BDO Consulting Group. That valuation is not speculative. It reflects the strategic necessity of the technology.
The engine utilizes proprietary “Hybrid Successive Approximation” (H-SA) to strip away non-critical computational paths. Instead of processing every data point, it focuses computational power exclusively on decision-relevant signals. The result is a collapse in processing time from minutes to milliseconds.
The applications are immediate. Radar systems, autonomous drones, and AI-driven threat detection all depend on speed. QuantumSpeed provides the velocity layer that transforms passive sensing into active response.
This acquisition redefines VisionWave’s market position. The company is no longer just building sensors. It is building the decision infrastructure for autonomous defense systems. The shift is from “seeing the threat” to “neutralizing the threat before the adversary acts.”
The market is pricing VisionWave as a small-cap defense contractor. The acquisition of a $99.6 million independently valued IP asset positions it as an infrastructure platform for the speed-dependent economy. The valuation gap is acute.
Read this and more news for VisionWave Holdings at:
https://equity-insider.com/2025/09/25/the-ai-defense-technology-developments-on-the-rise-in-2025-26/
THE ENERGY FUEL
Homeland Uranium Corp. (TSXV: HLU) is advancing its uranium projects at the exact moment the AI economy realizes it has an energy crisis.
The demand curve is vertical. Artificial intelligence, cryptocurrency mining, and electric vehicle charging are doubling electricity consumption every three years. Wind and solar cannot provide 24/7 baseload power. Batteries cannot store at the required scale.
Nuclear is the only zero-carbon solution that works when the sun sets and the wind stops.
Homeland is developing fuel sources for this new grid. The company controls assets including Coyote Basin and Red Wash in Colorado, positioning it within the domestic U.S. supply chain. This is not a commodity speculation. This is energy sovereignty.
The geopolitical context is accelerating demand. The United States cannot rely on Russian and Kazakh uranium while simultaneously expanding its nuclear fleet. Domestic production is a national security mandate, not an economic preference.
Homeland is drilling to prove what policymakers already know they need. The valuation disconnect exists because the market still treats uranium as a cyclical commodity. It is critical infrastructure for the AI era.
The gap between current enterprise value and the strategic necessity of domestic nuclear fuel is the asymmetry. As utilities secure long-term contracts and the government incentivizes domestic production, that gap closes.
Read this and more news for Homeland Uranium at:
https://equity-insider.com/2025/11/10/ai-needs-nuclear-2-5b-team-targets-upgrading-79-6m-lbs-historical-resource-estimate/
THE DISTRICT PLAY
Rua Gold (TSXV: RUA) (OTCQB: NZAUF) controls roughly 95% of the Reefton Goldfield in New Zealand, a district that historically produced over 2 million ounces of high-grade gold. This is not speculative geology. This is a proven mineral system in a Tier-1 jurisdiction.
With drilling wrapped and an updated resource estimate expected this month, Rua is transitioning from “concept” to “calculation.” The market is treating this as a junior explorer. The asset profile suggests a district-scale consolidation play.
The context matters. Major gold discoveries are increasingly rare. The last decade has seen declining reserve replacement at the world’s largest producers. Institutional capital is rotating toward advanced-stage assets in safe jurisdictions with proven mineralization.
Rua offers exactly that. A historic goldfield with 2 million ounces of past production, modern drilling confirming continuity, and a January resource update that will quantify the inventory. In a market where gold is approaching all-time highs and discovery risk is priced at a premium, Rua represents the alternative.
The valuation gap is temporary. As the resource estimate lands and the market recognizes the district-scale potential, the repricing begins. The bottleneck is not the gold. It is the time required to prove it.
Read this and more news for Rua Gold at:
https://equity-insider.com/2025/04/24/others-found-1911-g-t-here-before-now-a-proven-11b-mining-team-is-back-to-finish-the-job/
CONTACT:
Equity Insider
info@equity-insider.com
(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity-Insider.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). This article is being distributed for Baystreet.ca Media Corp. (“BAY”), who has been paid a fee of $75,000 for an advertising campaign. MIQ has not been paid a fee for GoldHaven Resources Corp. advertising or digital media, but the owner/operators of MIQ also co-owns BAY. There may also be 3rd parties who may have shares of GoldHaven Resources Corp. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. Specifically, readers should be aware that GoldHaven Resources Corp., Oncolytics Biotech Inc., VisionWave Holdings Inc., Homeland Uranium Corp., and Rua Gold are or have directly/indirectly been commercial clients of MIQ, Baystreet.ca Media Corp. (“BAY”), or their affiliates (entities under common ownership). The owner/operator of MIQ own shares of GoldHaven Resources Corp., Oncolytics Biotech Inc., VisionWave Holdings Inc., Homeland Uranium Corp., and Rua Gold which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of these companies at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by GoldHaven Resources Corp. The scientific and technical information disclosed in this document have been reviewed and approved by two Qualified Persons (QPs). The Copeçal Technical Report identifies Jean-Marc Lopez, B.Sc., FAusIMM, as the Qualified Person responsible for the report. The report “GoldHaven Resources Completes Summer Exploration Programs” states that the technical information has been reviewed and approved by Jonathan Victor Hill, B.Sc. Hons, FAusIMM, an independent Qualified Person and Country Manager of GoldHaven. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Regarding GoldHaven Resources Corp., Oncolytics Biotech Inc., VisionWave Holdings Inc., Homeland Uranium Corp., and Rua Gold, while the technical information contained herein is derived from official regulatory filings and news releases previously approved by the issuers’ designated Qualified Persons, this specific publication has not been independently reviewed, verified, or approved by those issuers. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
